Henan Lingrui Pharmaceutical Co., Ltd. (SHA:600285)
19.70
+0.03 (0.15%)
Aug 14, 2026, 3:00 PM CST
SHA:600285 Revenue
Henan Lingrui Pharmaceutical had revenue of 1.02B CNY in the quarter ending June 30, 2026, a decrease of -5.24%. This brings the company's revenue in the last twelve months to 3.90B, up 5.63% year-over-year. In the year 2025, Henan Lingrui Pharmaceutical had annual revenue of 3.85B with 10.07% growth.
Revenue (ttm)
3.90B
Revenue Growth
+5.63%
P/S Ratio
2.86
Revenue / Employee
1.40M
Employees
2,789
Market Cap
11.17B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.85B | 352.56M | 10.07% |
| Dec 31, 2024 | 3.50B | 189.36M | 5.72% |
| Dec 31, 2023 | 3.31B | 309.61M | 10.31% |
| Dec 31, 2022 | 3.00B | 308.35M | 11.45% |
| Dec 31, 2021 | 2.69B | 361.93M | 15.52% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Shyndec Pharmaceutical | 8.82B |
| Zhejiang Medicine | 8.82B |
| Zhejiang CONBA Pharmaceutical | 6.69B |
| Guobang Pharma | 6.13B |
| Tianjin Chase Sun Pharmaceutical Co.,Ltd | 4.68B |
| Zhejiang Jingxin Pharmaceutical | 4.04B |
| Mayinglong Pharmaceutical Group | 3.91B |
| Porton Pharma Solutions | 3.50B |